|
By Brian Wilson - Lead Contributor
|
|
Thursday, 17 October 2013 09:41 |
 Yesterday was the advisory committee meeting for the ANCHOR supplementary new drug application (sNDA) submitted for the drug Vascepa (icosapent ethyl) as a treatment for patients with TG >200 mg/dL and <500 mg/dL with mixed dyslipidemia.
|
|
Read more...
|
|
By Scott Matusow
|
|
Thursday, 17 October 2013 07:52 |
 At StockMatusow we strive to identify companies that we feel have the potential for both short and long term gains. This week we detail a company that we think could nearly double in value in the short term.
|
|
Read more...
|
|
By Brian Wilson - Lead Contributor
|
|
Tuesday, 15 October 2013 10:08 |
 One important question to ask when choosing investments in one particular industry is whether or not that industry is still attractive to investors looking at the big picture.
|
|
Read more...
|
|
By Scott Matusow
|
|
Tuesday, 15 October 2013 07:47 |
 At stockmatusow, we have compiled 5 of our best end of year, and long term small cap developmental biopharma companies we feel have an excellent chance to be longterm "multibaggers."
|
|
Read more...
|
|
By Brian Wilson-Lead Contributor
|
|
Sunday, 13 October 2013 18:34 |
 This article presumes that the reader is familiar with the general situation of Amarin Corporation ( NASDAQ: AMRN) and its drug Vascepa ahead of the ANCHOR advisory committee meeting and PDUFA goal date.
|
|
Read more...
|
|
By Scott Matusow
|
|
Friday, 11 October 2013 08:00 |
|
In the developmental biopharma segment of the market that we follow daily at stockmatusow, stock prices sometimes experience volatile moves, especially as a near-term catalyst event approaches.
|
|
Read more...
|
|
By Scott Matusow
|
|
Thursday, 10 October 2013 10:13 |
|
Halozyme (HALO) has a potential breakthrough in new therapeutic combination represents how pancreatic cancer has evaded standard treatments for patients.
|
|
Read more...
|
|
By Brian Wilson-Lead Contributor
|
|
Monday, 07 October 2013 07:41 |
|
Despite some easing of the hyper-bullish sentiment in the currently bloated specialty pharmaceuticals sector, Aegerion Pharmaceuticals (NASDAQ: AEGR) looks ready to finally breach the psychological $100/share mark. Despite some concerns over the small number of patients with HoFH (Homozygous familial hypercholesterolemia), Aegerion’s drug Juxtapid (lomitapide) was able to achieve incredibly high reimbursement payment for the drug – at $295,000 per patient.
|
|
Read more...
|
|
By Scott Matusow
|
|
Friday, 04 October 2013 14:01 |
|
Below, I show the AcelRx (NASDAQ: ACRX) charts and give some commentary why I believe it will hit $12 soon.
|
|
Read more...
|
|
By Brian Wilson - Lead Contributor
|
|
Friday, 04 October 2013 09:49 |
 Cytokinetics (NASDAQ: CYTK) seems to have stabilized just about $7.00 weeks after the company and partner Amgen (NASDAQ: AMGN) presented data from the 613 patient, randomized, double-blind and placebo-controlled Phase II study ATOMIC HF trial at the European Society of Cardiology Congress (ESC) on September 2nd, 2013.
|
|
Read more...
|
|
|
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>
|
|
Page 20 of 56 |
